PURPOSE: To evaluate the efficacy and safety of the combination of carboplatin plus paclitaxel in patients with advanced, metastatic and recurrent endometrial cancer. METHODS: Medical records were retrospectively reviewed to identify endometrial cancer patients treated in the Gynecologic Cancer Program of the Cleveland Clinic with carboplatin/paclitaxel who had both a histologic diagnosis of endometrial adenocarcinoma and either measurable (CT scan, physical examination) or evaluable (CA-125 criteria) disease. RESULTS: From 1994 to 2003, 22 individuals (median age 65 years) meeting the above noted criteria received a total of 23 courses of carboplatin (AUC 4-6)/paclitaxel (135-175 mg/m2) administered on a 21-day schedule (median six cycles/patient). The overall response rate was 87% (20/23). The most common toxicity was hematologic. Five patients required dose reductions due to excessive toxicity (three hematologic, one gastrointestinal, one fatigue). There were no treatment related deaths. With a median follow-up of 42 months, 13 patients have died of progressive cancer, while four currently have no evidence of disease at the time of last follow-up. CONCLUSIONS: The combination of carboplatin plus paclitaxel demonstrates substantial biological activity in endometrial adenocarcinoma. The safety and efficacy of this regimen makes it an attractive option for first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma.
PURPOSE: To evaluate the efficacy and safety of the combination of carboplatin plus paclitaxel in patients with advanced, metastatic and recurrent endometrial cancer. METHODS: Medical records were retrospectively reviewed to identify endometrial cancerpatients treated in the Gynecologic Cancer Program of the Cleveland Clinic with carboplatin/paclitaxel who had both a histologic diagnosis of endometrial adenocarcinoma and either measurable (CT scan, physical examination) or evaluable (CA-125 criteria) disease. RESULTS: From 1994 to 2003, 22 individuals (median age 65 years) meeting the above noted criteria received a total of 23 courses of carboplatin (AUC 4-6)/paclitaxel (135-175 mg/m2) administered on a 21-day schedule (median six cycles/patient). The overall response rate was 87% (20/23). The most common toxicity was hematologic. Five patients required dose reductions due to excessive toxicity (three hematologic, one gastrointestinal, one fatigue). There were no treatment related deaths. With a median follow-up of 42 months, 13 patients have died of progressive cancer, while four currently have no evidence of disease at the time of last follow-up. CONCLUSIONS: The combination of carboplatin plus paclitaxel demonstrates substantial biological activity in endometrial adenocarcinoma. The safety and efficacy of this regimen makes it an attractive option for first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma.
Authors: D V Skarlos; G Aravantinos; P Kosmidis; A Athanassiadis; G P Stathopoulos; N Pavlidis; D Bafaloukos; S Karphathios; P Papakostas; C Bamia; G Fountzilas Journal: Semin Oncol Date: 1997-10 Impact factor: 4.929
Authors: G F Fleming; J M Fowler; S E Waggoner; L J Copeland; B E Greer; I Horowitz; G Sutton; R J Schilder; P M Fracasso; H G Ball; W P McGuire Journal: J Clin Oncol Date: 2001-02-15 Impact factor: 44.544
Authors: A Vasuratna; A P Kudelka; C L Edwards; V Wootipoom; C F Verschraegen; C Charnsangavej; J J Kavanagh Journal: Anticancer Drugs Date: 1998-03 Impact factor: 2.248
Authors: T W Burke; A Munkarah; J J Kavanagh; M Morris; C Levenback; C Tornos; D M Gershenson Journal: Gynecol Oncol Date: 1993-12 Impact factor: 5.482
Authors: Melissa A Geller; Joseph J Ivy; Rahel Ghebre; Levi S Downs; Patricia L Judson; Linda F Carson; Amy L Jonson; Kathryn Dusenbery; Rachel Isaksson Vogel; Matthew P Boente; Peter A Argenta Journal: Gynecol Oncol Date: 2011-01-15 Impact factor: 5.482